Update on Statin Treatment in Patients with Neuropsychiatric Disorders

被引:23
作者
Avan, Razieh [1 ]
Sahebnasagh, Adeleh [2 ]
Hashemi, Javad [3 ]
Monajati, Mahila [4 ]
Faramarzi, Fatemeh [5 ]
Henney, Neil C. [6 ]
Montecucco, Fabrizio [7 ,8 ]
Jamialahmadi, Tannaz [9 ]
Sahebkar, Amirhossein [10 ,11 ,12 ]
机构
[1] Birjand Univ Med Sci, Sch Pharm, Dept Clin Pharm, Med Toxicol & Drug Abuse Res Ctr MTDRC, Birjand 9717853577, Iran
[2] North Khorasan Univ Med Sci, Dept Internal Med, Clin Res Ctr, Bojnurd 9453155166, Iran
[3] North Khorasan Univ Med Sci, Sch Med, Dept Pathobiol & Lab Sci, Bojnurd 9453155166, Iran
[4] Golestan Univ Med Sci, Dept Internal Med, Gorgan 4934174515, Golestan, Iran
[5] Iran Univ Med Sci, Clin Pharm Res Ctr, Tehran 1445613131, Iran
[6] Liverpool John Moores Univ, Pharm & Biomol Sci, Liverpool L3 5UX, Merseyside, England
[7] IRCCS Osped Policlin San Martino Genoa, Italian Cardiovasc Network, 10 Largo Benzi, I-16132 Genoa, Italy
[8] Univ Genoa, Dept Internal Med, Clin Internal Med 1, 6 Viale Benedetto XV, I-16132 Genoa, Italy
[9] Mashhad Univ Med Sci, Dept Nutr, Fac Med, Mashhad 9177948564, Razavi Khorasan, Iran
[10] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran
[11] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad 9177948954, Razavi Khorasan, Iran
[12] Mashhad Univ Med Sci, Sch Pharm, Dept Biotechnol, Mashhad 9177948954, Razavi Khorasan, Iran
来源
LIFE-BASEL | 2021年 / 11卷 / 12期
关键词
statins; neuropsychiatric disorders; clinical trials; adverse effects; major depressive disorder; schizophrenia; anxiety; obsessive-compulsive disorder; bipolar disorder; delirium; autism spectrum disorders; MAJOR DEPRESSIVE DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; SEVERE MENTAL-ILLNESS; DOUBLE-BLIND; BIPOLAR DISORDER; NITRIC-OXIDE; CHOLESTEROL REDUCTION; ADJUNCTIVE TREATMENT; CYTOKINE ALTERATIONS;
D O I
10.3390/life11121365
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuropsychiatric disorders. In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of electronic databases. We also explored the adverse effects of these drugs to obtain insights into the benefits and risks associated with their use in the treatment of these disorders. Lipophilic statins (including simvastatin) because of better brain penetrance may have greater protective effects against MDD and schizophrenia. The significant positive effects of statins in the treatment of anxiety disorders without any serious adverse side effects were shown in numerous studies. In OCD, BD, and delirium, limitations, and contradictions in the available data make it difficult to draw conclusions on any positive effect of statins. The positive effects of simvastatin in autism disorders have been evaluated in only a small number of clinical trials. Although some studies showed positive effect of statins in some neuropsychiatric disorders, further prospective studies are needed to confirm this and define the most effective doses and treatment durations.
引用
收藏
页数:23
相关论文
共 179 条
  • [21] The neuroinflammatory hypothesis of delirium
    Cerejeira, Joaquim
    Firmino, Horacio
    Vaz-Serra, Adriano
    Mukaetova-Ladinska, Elizabeta B.
    [J]. ACTA NEUROPATHOLOGICA, 2010, 119 (06) : 737 - 754
  • [22] Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial
    Chaudhry, Imran B.
    Husain, Nusrat
    Husain, Mohammad O.
    Hallak, Jamie
    Drake, Richard
    Kazmi, Ajmal
    Rahman, Raza Ur
    Hamirani, Mohammad M.
    Kiran, Tayyaba
    Mehmood, Nasir
    Stirling, John
    Dunn, Graham
    Deakin, Bill
    [J]. TRIALS, 2013, 14
  • [23] Hyperlipidemia, statin use and the risk of developing depression: a nationwide retrospective cohort study
    Chuang, Chieh-Sen
    Yang, Tse-Yen
    Muo, Chih-Hsin
    Su, Hong-Lin
    Sung, Fung-Chang
    Kao, Chia-Hung
    [J]. GENERAL HOSPITAL PSYCHIATRY, 2014, 36 (05) : 497 - 501
  • [24] Interpretation of the evidence for the efficacy and safety of statin therapy
    Collins, Rory
    Reith, Christina
    Emberson, Jonathan
    Armitage, Jane
    Baigent, Colin
    Blackwell, Lisa
    Blumenthal, Roger
    Danesh, John
    Smith, George Davey
    DeMets, David
    Evans, Stephen
    Law, Malcolm
    MacMahon, Stephen
    Martin, Seth
    Neal, Bruce
    Poulter, Neil
    Preiss, David
    Ridker, Paul
    Roberts, Ian
    Rodgers, Anthony
    Sandercock, Peter
    Schulz, Kenneth
    Sever, Peter
    Simes, John
    Smeeth, Liam
    Wald, Nicholas
    Yusuf, Salim
    Peto, Richard
    [J]. LANCET, 2016, 388 (10059) : 2532 - 2561
  • [25] Systemic inflammation and delirium: important co-factors in the progression of dementia
    Cunningham, Colm
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 945 - 953
  • [26] Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study
    Dave, Chintan V.
    Winterstein, Almut G.
    Park, Haesuk
    Cook, Robert L.
    Hartzema, Abraham G.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2018, 238 : 542 - 546
  • [27] Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder
    De Hert, Marc
    Kalnicka, Dita
    van Winkel, Ruud
    Wampers, Martien
    Hanssens, Linda
    Van Eyck, Dominique
    Scheen, Andre
    Peuskens, Joseph
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (12) : 1889 - 1896
  • [28] Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial
    Dean, Olivia May
    Maes, Michael
    Ashton, Melanie
    Berk, Lesley
    Kanchanatawan, Buranee
    Sughondhabirom, Atapol
    Tangwongchai, Sookjareon
    Ng, Chee
    Dowling, Nathan
    Malhi, Gin S.
    Berk, Michael
    [J]. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2014, 12 (03) : 180 - 188
  • [29] Decloedt EH, 2010, NEUROPSYCH DIS TREAT, V6, P233
  • [30] Diamantis E, 2017, CURR CARDIOL REV, V13, P209, DOI 10.2174/1573403X13666170426104611